Browsing Medicine by Author "http://dx.doi.org/10.13039/100011102"
Now showing items 1-3 of 3
-
Hypoxia activates the PTHrP-MEF2C pathway to attenuate hypertrophy in mesenchymal stem cell derived cartilage
Browe, David C.; Coleman, Cynthia M.; Barry, Frank P.; Elliman, Stephen J. (Nature Research, 2019-09-16)Articular cartilage lacks an intrinsic repair capacity and due to the ability of mesenchymal stem cells (MSCs) to differentiate into chondrocytes, MSCs have been touted as a cellular source to regenerate damaged cartilage. ... -
Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation
Lohan, Paul; Murphy, Nick; Treacy, Oliver; Lynch, Kevin; Morcos, Maurice; Bingling, Chen; Ryan, Aideen E.; Griffin, Matthew D.; Ritter, Thomas (Frontiers Media, 2018-11-20)High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. ... -
TNF-a/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung.
Murphy, Nick; Treacy, Oliver; Lynch, Kevin; Morcos, Maurice; Lohan, Paul; Howard, Linda; Fahy, Gerry; Griffin, Matthew D.; Ryan, Aideen E.; Ritter, Thomas (Federation of American Society of Experimental Biology (FASEB), 2019-05-20)Mesenchymal stromal cells (MSCs) have shown promise as a therapy for immune-mediated disorders, including transplant rejection. Our group previously demonstrated the efficacy of pretransplant, systemic administration of ...